SCHEMBL1642243

SCHEMBL1642243

O=C(O)CNC(=O)c1c(O)c(C(=O)NCc2ccc(Cl)c(Cl)c2)cn(Cc2ccc(Br)cc2)c1=O

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 6/20 0.69
CNR1 P21554 2/20 0.47
CNR2 P34972 1/20 0.47
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EGLN1 Q9GZT9 5/20 0.43
HIF1A Q16665 1/20 0.42
AKR1B1 P15121 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
TAOK3 Q9H2K8 1/20 0.41
EGLN2 Q96KS0 3/20 0.40
APEX1 P27695 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641775 0.93 EGLN3 (0.81) EGLN3CNR1HPGDMEN1KMT2A
SCHEMBL12727502 0.91 EGLN3 (0.69) EGLN3CNR1CNR2HPGDSMN1; SMN2
SCHEMBL12727509 0.90 EGLN3 (0.68) EGLN3CNR1CNR2EGLN1HIF1A
SCHEMBL1641104 0.90 EGLN3 (0.58) EGLN3CNR1CNR2HPGDMEN1
SCHEMBL1642095 0.88 EGLN3 (0.66) EGLN3HPGDEGLN1HIF1AEGLN2
SCHEMBL1642303 0.87 EGLN3 (0.69) EGLN3CNR1MEN1KMT2ASMN1; SMN2
SCHEMBL1642028 0.85 EGLN3 (0.61) EGLN3CNR1CNR2EGLN1HIF1A
SCHEMBL1640737 0.84 EGLN3 (0.60) EGLN3CNR1CNR2SMN1; SMN2HIF1A
SCHEMBL12727499 0.83 EGLN3 (0.58) EGLN3CNR1CNR2EGLN1HIF1A
SCHEMBL1642313 0.82 EGLN3 (0.57) EGLN3CNR1CNR2EGLN1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885CNR1 2636/4885CNR2 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.